<DOC>
	<DOCNO>NCT00857389</DOCNO>
	<brief_summary>The goal clinical research study learn thiotepa , busulfan , clofarabine , give allogeneic ( bone marrow , blood , cord blood cell ) haploidentical ( bone marrow ) stem cell transplantation help control cancers bone marrow lymph node system . The safety treatment also study .</brief_summary>
	<brief_title>Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant High Risk Malignancies</brief_title>
	<detailed_description>The Study Drugs : Thiotepa busulfan design bind DNA ( genetic material cell ) , may cause cancer cell die . They commonly use stem cell transplant . Clofarabine design interfere growth development cancer cell . Study Drug Administration : If find eligible take part study , begin receive study drug receive stem cell transplant . On Day -8 ( 8 day receive stem cell transplant ) , receive thiotepa central venous catheter ( CVC ) 2 hour . A CVC sterile , flexible tube place large vein local anesthesia . Your doctor explain procedure detail , require sign separate consent form procedure . On Day -7 , receive busulfan CVC . This dose busulfan low level `` test '' dose check blood level change time . This information use decide next dose level busulfan . Blood ( 1 teaspoon time ) drawn 6-11 time total Days -7 -5 pharmacokinetic ( PK ) test . PK test measure amount busulfan body different time point . This PK test do find dose busulfan need body size day receive busulfan . A heparin lock line place vein low number need stick perform draw . If blood level test perform reason , receive standard busulfan dose . On Days -6 , -5 , -4 , -3 , receive clofarabine CVC 1 hour . On Days -5 , -4 , -3 , receive busulfan CVC 3 hour . On Days -4 -3 also receive antithymocyte globulin ( ATG ) vein 4 hour . This help reduce risk body reject transplant . If transplant involve haploidentical stem cell , receive ATG Days -4 -3 . On Days -2 -1 , `` rest , '' mean give drug , CVC remain place . Stem Cell Transplant : On Day 0 , allogeneic haploidentical stem cell transplant CVC . Allogeneic stem cell come donor whose cell closely match cell . Haploidentical stem cell come donor whose cell match cell closely , specially process help prevent graft versus host disease ( GVHD ) . Receiving stem cell similar receive blood transfusion . The time require receive stem cell depend type cell receive . Receiving cord blood stem cell take several minute . Receiving bone marrow blood stem cell may take several hour . You receive G-CSF ( filgrastim ) ( help produce white blood cell ) injection skin day , start 1 week transplant , blood cell level return normal . You receive drug ( mycophenolate mofetil ( MMF ) , tacrolimus and/or methotrexate ) help prevent side effect , GVHD . You receive methylprednisolone develop GVHD . You stay hospital 4 week stem cell transplantation . If haploidentical stem cell transplant , Days 3 4 stem cell transplant , receive cyclophosphamide CVC 30-60 minute . Mesna give vein time give dose cyclophosphamide , help protect bladder bleeding . Study Visits : Beginning Day -9 , day hospital : - You physical exam , include measurement vital sign . - You ask side effect . - Blood ( 4 tablespoon ) draw test blood cell count . Two ( 2 ) time week , blood also use routine test . After hospital , 2 time month 100 day transplant : - You physical exam , include measurement vital sign weight . - You ask side effect . - Blood ( 4 tablespoon ) draw routine test . About 1 , 3 , 6 , 12 month transplant , blood ( 4 tablespoon ) draw check status disease . You also bone marrow aspiration check status disease . You also physical exam . If doctor think necessary , may extra test procedure . Length Study : You study 1 year . You take study disease get bad need treatment . Follow-Up : If live close M. D. Anderson , return clinical every several month physical exam . At visit , blood ( 3 teaspoon ) draw routine test . You and/or local doctor call every several month ask health status leukemia MDS come back . This investigational study . Thiotepa clofarabine FDA approve commercially available treatment leukemia . Busulfan FDA approve commercially available use stem cell transplantation . The combination thiotepa , clofarabine , busulfan together stem cell transplant investigational . Up 60 participant take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<criteria>1 . Diagnosed one follow disease : 2 . Acute myelogenous leukemia ( AML ) induction failure , relapse , past first remission , CR1 consider risk relapse 3 . Myelodysplastic syndrome International Prognostic Scoring System score ( IPSS score ) &gt; /= 2 myelodysplasia respond chemotherapy 4 . Biphenotypic leukemia 5 . Acute lymphocytic leukemia induction failure , first complete remission high risk cytogenetics ( e.g . Philadelphia positive chromosome , ( 4:11 ) Remission require 2 chemotherapy achieve remission , stage beyond CR1 6 . Chronic Myelogenous Leukemia ( CML ) : second chronic phase , accelerate phase blast crises less 10 % blast bone marrow , CR1 resistance Gleevec tyrosine kinase inhibitor 7 . NonHodgkin 's Lymphoma induction failure , second third complete remission , relapse ( include relapse post autologous hematopoietic stem cell transplant ) 8 . Hodgkin 's disease induction failure , second later complete remission , relapse ( include relapse post autologous hematopoietic stem cell transplant ) . 9 . Chronic Lymphocytic Leukemia fail induction therapy Rai Stages 24 10 . Related unrelated donor HLAmatched mismatch 1 HLA A , B , C , DR , DQ locus acceptable ( i.e . &gt; /= 9/10 match relate unrelated donor , match molecular highresolution technique per current std . BMT program ) . Cord blood unit must match patient 4 , 5 , 6/6 HLA class 1 serological &amp; II molecular antigen min . 2 x 10e7 TNC/kg recipient weight prethawed fraction . For patient lack match related unrelated donor acceptable cord blood unit ( ) , related haploidentical donor ( &lt; /= 7/8 allele match A , B , C , DR locus ) may use . 11 . Age &lt; /= 60 year . 12 . Lansky performance score &gt; /= 50 % patient &lt; /= 16 year age , Zubrod performance status score 02 patient &gt; 16 year age . 13 . Cardiac function leave ventricular ejection fraction &gt; /= 40 % . 14 . Pulmonary function diffusion capacity least 50 % predict . Children unable perform pulmonary function test ( e.g . le 7 year old ) pulse oximetry &gt; /= 92 % room air . 15 . Serum creatinine &lt; 1.6 mg/dL creatinine clearance &gt; /= 50 ml/min . 16 . SGPT &lt; /= 200 IU/mL , serum bilirubin &lt; 1.5 x normal . 17 . Written inform consent assent age appropriate . 18 . No active infection . 1 . Pregnancy woman child bear potential ( pregnancy test perform within 2 week study entry ) . 2 . HIV positive ( highly immunosuppressive treatment ) 3 . Active CNS leukemia 4 . Chronic active Hepatitis B Hepatitis C. If question liver health discus PI strongly consider liver biopsy .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Blood And Marrow Transplantation</keyword>
	<keyword>Stem Cell</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Pediatrics</keyword>
	<keyword>Bone marrow</keyword>
	<keyword>Lymph node system</keyword>
	<keyword>Allogeneic Stem Cell Transplant</keyword>
	<keyword>ASCT</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Busulfex</keyword>
	<keyword>Myleran</keyword>
	<keyword>Clofarabine</keyword>
	<keyword>Clofarex</keyword>
	<keyword>Clolar</keyword>
	<keyword>Thiotepa</keyword>
	<keyword>Antithymocyte globulin</keyword>
	<keyword>ATG</keyword>
	<keyword>Thymoglobulin</keyword>
	<keyword>G-CSF</keyword>
	<keyword>Filgrastim</keyword>
	<keyword>Neupogen</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Cytoxan</keyword>
	<keyword>Neosar</keyword>
	<keyword>Mesna</keyword>
	<keyword>Mesnex</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Prograf</keyword>
	<keyword>Methotrexate</keyword>
</DOC>